K-Glim-Trio 2mg Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2mg, Metformin 500mg, and Voglibose 0.2mg, formulated for sustained release to optimize glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, enhances pancreatic insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, effectively reducing postprandial hyperglycemia. The combined action of these agents targets multiple pathophysiological defects in type 2 diabetes, offering comprehensive glycemic management. K-Glim-Trio 2mg Tablet SR is indicated for patients inadequately controlled on monotherapy or dual therapy, providing improved efficacy with a convenient once-daily dosing regimen. It is essential to monitor blood glucose levels regularly and adjust therapy based on clinical response and tolerability. Common side effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, as well as hypoglycemia, particularly due to sulfonylurea action. This medication should be used with caution in patients with renal or hepatic impairment and is contraindicated in individuals with type 1 diabetes, diabetic ketoacidosis, or known hypersensitivity to any component.